FDA/PhRMA Task Force To Assess QT Risk By Preclinical Markers
Executive Summary
FDA and the Pharmaceutical Research & Manufacturers of America are forming a joint task force to define a preclinical threshold to serve as a predictor for the risk of drug-associated QT prolongation.
You may also be interested in...
Searching For Surrogate Endpoints Requires Teamwork
Discussions between FDA and researchers during a workshop on the fatty liver conditions NAFLD/NASH clarified the status of potential surrogate endpoints for clinical trials, but indicated that much work remains to be done to ready the various options for use – and that will likely need to be a joint effort.
Glaxo Withdraws Raxar Following Seven Fatal Cardiovascular AEs
Glaxo Wellcome is withdrawing the quinolone antibiotic Raxar (grepafloxacin) from the worldwide markets after receiving a total of seven reports of cardiovascular event-related fatalities associated with use of the drug.
Glaxo Withdraws Raxar Following Seven Fatal Cardiovascular AEs
Glaxo Wellcome is withdrawing the quinolone antibiotic Raxar (grepafloxacin) from the worldwide markets after receiving a total of seven reports of cardiovascular event-related fatalities associated with use of the drug.